Episode
A conversation with Dr. Thomas Kline & Jonelle Elgaway of the National Pain Council
Today we are here with Dr. Thomas Kline and Jonelle Elgaway, of the National Pain Council, a citizen's group with ...
A conversation with Mr. Adam Marcus, co-founder of Retraction Watch and editor for Primary Care at Medscape
We discuss the rise in retractions among academic publications, and the pandemic's impact on retractions in clinical journals over the ...
A conversation with Dr. John Whyte, Chief Medical Officer of WebMD and author of the new book, Take Control of Your Diabetes Risk
We discuss Dr. John Whyte's latest book, Take Control of Your Diabetes Risk, and reveal what it offers patients struggling ...
A conversation with Miss Tara Haelle, a health journalist and subject matter expert on vaccines
We discuss Miss Haelle's struggles to overcome vaccine misinformation during the pandemic. As a journalist, she often found herself at ...
A conversation with Miss Sandra Lamb, an award winning journalist and author
We discuss Miss Lamb’s experiences during the pandemic and glean her thoughts on how it affected the quality of writing ...
A conversation with Miss Andrea King Collier, author and award winning health journalist
We discuss her journalism as a writer and lived experiences as a patient during the pandemic, chronicling a timeline of ...
A conversation with Mr. John Tassoni, addiction policy expert and lobbyist at The Sentinel Group
We discuss addiction policies in Rhode Island and demonstrate how bureaucracies can influence the passing of addiction policy and law. ...
A conversation with Miss Leah Samuel, health and equity editor for The Conversation
We discuss health and equity in a post-pandemic world. While health and equity may be the future of medicine, its ...
A conversation with Mr. Ron Chapman, of Chapman Law Group, on Ruan v. United States
We discuss the oral arguments presented on March 1st in the seminal case, Ruan v. United States - arguably the ...
A conversation with Dr. Jeff Singer, Senior Fellow at the Cato Institute
We discuss the proposed changes to the CDC opioid prescribing guidelines and challenge false notions on opioids, prohibition, and addiction. ...
A conversation with Miss Bev Schechtman, Vice President of The Doctor Patient Forum
We discuss Miss Schechtman's journey from a patient to a patient advocate, who through her platform now empowers patients suffering ...
A conversation with Mr. David Levine, co-Chair of Co-Chair Science Writers in New York
We discuss the past, present, and future of healthcare journalism, gleaning lessons learned over the pandemic to predict upcoming trends. ...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more